Logo MSM

27 August 2003

A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy

Deborah L. Toppmeyer, Murugesan Gounder, Judie Much, Rita Musanti, Viral Vyas, Melissa Medina, Tammy Orlando, Michael Pennick, Yong Lin, Weichung Shih, Susan Goodin, Eric H. Rubin

Med Sci Monit 2003; 9(8): PI99-104 :: ID: 13110


BACKGROUND: Marimastat is a potent inhibitor of matrix metalloproteinases and in preclinical studies enhances the anti-tumor activity of certain chemotherapeutics. We performed a phase I clinical evaluation of the combination of oral marimastat and intravenous paclitaxel, to determine if these drugs could be co-administered safely, and to determine whether marimastat alters paclitaxel pharmacokinetics.Material/Methods:Marimastat was administered twice daily and paclitaxel as a three hour infusion every three weeks. Doses of both marimastat and paclitaxel were escalated in cohorts of patients up to maximal doses of 10 mg for marimastat and 175 mg/m2 for paclitaxel. Paclitaxel plasma pharmacokinetic parameters were assessed in the absence (cycle 1) and presence (cycle 2) of marimastat. Trough marimastat plasma levels were evaluated during cycle 2.Results:A total of 19 patients were treated at three different dose levels. There were no dose-limiting toxicities during the first cycle of therapy, resulting in dose escalation up to the planned maximal dose for each drug. Neutropenia was the most common significant toxicity at the highest dose level, with grade 3 or higher neutropenia occurring in 38% of patients. There were no complete or partial responses. Pharmacokinetic analyses indicate that marimastat does not alter paclitaxel clearance. At the 10 mg dose, the mean trough marimastat level was 14.8 Kg/L.Conclusions:Marimastat and paclitaxel can be co-administered safely at doses equivalent to those recommended for single-agent administration. Additional studies are necessary to determine whether this combination is more effective in controlling tumor progression than paclitaxel alone.

Keywords: Adult, Antineoplastic Agents, Phytogenic - chemistry, Antineoplastic Agents, Phytogenic - pharmacokinetics, Antineoplastic Agents, Phytogenic - therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Enzyme Inhibitors - chemistry, Enzyme Inhibitors - pharmacokinetics, Enzyme Inhibitors - therapeutic use, Hydroxamic Acids - chemistry, Hydroxamic Acids - pharmacokinetics, Hydroxamic Acids - therapeutic use, Molecular Structure, Neoplasms - drug therapy, Paclitaxel - chemistry, Paclitaxel - pharmacokinetics, Paclitaxel - therapeutic use


This Week Editorial

02 August 2021 : Editorial

Editorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.934171

Med Sci Monit 2021; 27:e934171

Coronavirus/Covid 19

30 July 2021 : Clinical Research

Rural and Female Patients with Old Myocardial Infarction Lacked Knowledge and Preventive Measures During th...

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.928512  

16 July 2021 : Review article

Silent Hypoxemia in Patients with COVID-19 Pneumonia: A Review

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.930776  

09 July 2021 : Database Analysis

A Simple Clinical Prediction Tool for COVID-19 in Primary Care with Epidemiology: Temperature-Leukocytes-CT...

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.931467  

07 July 2021 : Database Analysis

Chest Radiological Findings and Clinical Characteristics of Laboratory-Confirmed COVID-19 Patients from Sau...

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.932441  

In Press

03 Aug 2021 : Clinical Research

Comparison of Outcomes Following TiRobot-Assisted Sacroiliac Screw Fixation with Bone Grafting and Traditio...

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.932724  

02 Aug 2021 : Database Analysis

RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape...

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.930994  

02 Aug 2021 : Clinical Research

Vitamin D Receptor Is a Sepsis-Susceptibility Gene in Chinese Children

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.932518  

30 Jul 2021 : Clinical Research

Rural and Female Patients with Old Myocardial Infarction Lacked Knowledge and Preventive Measures During th...

Med Sci Monit In Press  ::  DOI: 10.12659/MSM.928512  

Most Viewed

20 Mar 2020 : Clinical Research

Social Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...

DOI :10.12659/MSM.923921

Med Sci Monit 2020; 26:e923921

15 Apr 2020 : Clinical Research

Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...

DOI :10.12659/MSM.924171

Med Sci Monit 2020; 26:e924171

05 May 2020 : Review article

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development

DOI :10.12659/MSM.924700

Med Sci Monit 2020; 26:e924700

26 Apr 2020 : Clinical Research

Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus P...

DOI :10.12659/MSM.924609

Med Sci Monit 2020; 26:e924609

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750